Nasus Pharma Partners with Aptar France and AptarGroup for NS002 Development
I'm PortAI, I can summarize articles.
Nasus Pharma Ltd. has expanded its collaboration with Aptar France S.A.S. and AptarGroup Inc. to advance the clinical development and commercialization of NS002, an intranasal epinephrine powder. The partnership grants Nasus access to Aptar's Unit Dose System technology, aiming to expedite NS002's market entry by utilizing established regulatory and supply chain capabilities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments